Rituximab biosimilars
Author:
Publisher
Informa Healthcare
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
http://www.tandfonline.com/doi/pdf/10.1517/14712598.2013.787064
Reference129 articles.
1. The advent of biosimilar therapies in rheumatology—“O Brave New World”
2. The FDA's assessment of follow-on protein products: a historical perspective
3. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
4. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
5. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comprehensive genetic and functional analysis of FcγRs in rituximab therapy for autoimmunity reveals a key role for FcγRIIIa on NK cells;2021-08-28
2. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars;Future Oncology;2021-07
3. Availability, affordability and drug utilization of biosimilar medicinal products, containing monoclonal antibodies in Bulgaria;Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector;2021-05-20
4. Hydrogen deuterium exchange mass spectrometry identifies the dominant paratope in CD20 antigen binding to the NCD1.2 monoclonal antibody;Biochemical Journal;2021-01-13
5. OUP accepted manuscript;Rheumatology;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3